Chinese medicine 6 new drug ginseng pills approved clinical trial license to treat spinal cervical vertebral disease

　　Medicine Network March 17 - Recently, Shanghai and Huang Pharmaceutical Co., Ltd and Shanghai University of Traditional Chinese Medicine affiliated longhua hospital co-development of the Chinese medicine 6 new drugs, ginseng pills approved by the State Drug Administration (NMPA) clinical trial license, clinically intended to treat light, moderate spinal cord-type cervical vertebral disease (Chinese medicine dialectical is a gas-deprived blood hysteria kidney loss certificate) cervical vertebral disease can be divided into cervical, nerve root, spinal cord, other types (vertebraartery type, sympathetic type) Cervical cervical vertebral disease (Cervical pondylotic myelopathy, CSM) refers to the cervical vertebral disease, which causes 10% of all cervical vertebral vertebral disease stoicism due to the small cervical vertebral joint and intervertebral disc retreat, and the secondary formation of vertebral vertebral bone, which in this way compresses or dominates the blood vessels of the spinal cord, causing the spinal cord stenosis and leading to chronic compression or/and spinal cord blood supply disorders and causing the associated spinal cord dysfunction At present, the treatment of clinical CSM is lacking drugs that can effectively control the development of its condition and promote patient function recovery Nonsteroidal anti-inflammatory drugs, glucocorticoids, neurotrophic drugs, surgical intervention are modern medical CSM conventional treatment methods The purpose of drug treatment is to control the patient's pain, numbness and other symptoms, and lack of the role of relieving neuropathy Although the surgical intervention is more accurate to CSM, there are also shortcomings such as higher postoperative complications and poor function recovery after reduced stress Based on the above reasons, seeking further effective and safe intervention cSM, and can be used in clinical treatment quickly, is the focus of drug research and development In May 2015, Shanghai and Huang Pharmaceutical Co., Ltd and Longhua , affiliated with Shanghai Zhong
University, jointly developed a new class of 6 new Chinese medicine, ginseng pills The clinical value of the new drug development lies in the early and medium-term prevention of spinal cervical vertebral disease and the late surgical treatment to solve the problems of local inflammation, ischemia or blood stimulation caused by the spinal cord continued to damage, improve the clinical efficacy, can fill the current clinical treatment drug gap for spinal cord cervical vertebral disease, has important development value and clinical significance.